| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0000278 | Mitotic cell cycle | Decreases phenotype | PMID:19049291 |
| GO:0004030 | Aldehyde dehydrogenase [nad(p)+] activity | Decreases phenotype | PMID:24491970 |
| GO:0006874 | Cellular calcium ion homeostasis | Affects phenotype | PMID:27784618 |
| GO:0006915 | Apoptotic process | Increases phenotype | PMID:33930522 |
| GO:0006974 | Cellular response to dna damage stimulus | Increases phenotype | PMID:19591892; PMID:33930522 |
| GO:0008283 | Cell population proliferation | Decreases phenotype | PMID:19049291 |
| GO:0008284 | Positive regulation of cell population proliferation | Increases phenotype | PMID:25324206 |
| GO:0010942 | Positive regulation of cell death | Increases phenotype | PMID:20654549 |
| GO:0010972 | Negative regulation of g2/m transition of mitotic cell cycle | Increases phenotype | PMID:25543211 |
| GO:0043065 | Positive regulation of apoptotic process | Increases phenotype | PMID:25530041 |
| GO:0043966 | Histone h3 acetylation | Increases phenotype | PMID:25543211 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:33930522 |
| GO:0045931 | Positive regulation of mitotic cell cycle | Decreases phenotype | PMID:25530041 |
| GO:0060765 | Regulation of androgen receptor signaling pathway | Affects phenotype | PMID:25324206 |
| GO:0070507 | Regulation of microtubule cytoskeleton organization | Decreases phenotype | PMID:25543211 |
| GO:0071629 | Cytoplasm protein quality control by the ubiquitin-proteasome system | Decreases phenotype | PMID:23988235 |
| GO:0071929 | Alpha-tubulin acetylation | Increases phenotype | PMID:25543211 |
| GO:0072593 | Reactive oxygen species metabolic process | Affects phenotype | PMID:33930522 |
| GO:1901165 | Positive regulation of trophoblast cell migration | Decreases phenotype | PMID:25530041 |
| GO:1903409 | Reactive oxygen species biosynthetic process | Increases phenotype | PMID:27784618 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.